真实世界队列中伊布替尼治疗期间BTKC481S突变的筛查与监测
该研究对83例接受单药伊布替尼治疗的复发/难治性慢性淋巴细胞白血病患者进行敏感性为10-4的时间分辨BTKC481S突变筛查,中位随访40个月。在32例进展患者中,突变出现较临床复发症状中位提前9个月。后续Bcl-2抑制治疗在28/32例携带BTKC481S且进展的患者中带来临床和分子缓解。
要点
- 突变出现较临床复发症状中位提前9个月,可早期预测复发。
- 携带BTKC481S且进展者后续Bcl-2抑制治疗可获得临床和分子缓解。
核心结论
- 敏感性BTKC481S监测可早期预测伊布替尼治疗的复发/难治CLL患者的疾病进展。
研究设计与样本
- 在83例接受单药伊布替尼治疗的复发/难治性CLL患者中进行敏感性为10-4的时间分辨BTKC481S突变筛查,中位随访40个月。
主要发现
- 在32例进展患者中,BTKC481S突变出现较临床复发症状中位提前9个月。
- 32例携带BTKC481S且进展的患者中,28例后续接受Bcl-2抑制治疗并获得临床和分子缓解。
关键数值与推荐
- BTKC481S突变筛查敏感性为10-4。
- BTKC481S突变出现较临床复发症状中位提前9个月。
临床怎么用
- 对伊布替尼治疗的复发/难治CLL患者可考虑敏感性BTKC481S监测以早期预测复发。
- 检出BTKC481S突变且疾病进展者,后续Bcl-2抑制治疗可能获得临床和分子缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has revolutionised the therapeutic landscape of chronic lymphocytic leukaemia (CLL). Acquired mutations emerging at position C481 in the BTK tyrosine kinase domain are the predominant genetic alterations associated with secondary ibrutinib resistance. To assess the correlation between disease progression, and the emergence and temporal dynamics of the most common resistance mutation BTKC481S , sensitive (10-4 ) time-resolved screening was performed in 83 relapsed/refractory CLL patients during single-agent ibrutinib treatment. With a median follow-up time of 40 months, BTKC481S was detected in 48·2% (40/83) of the patients, with 80·0% (32/40) of them showing disease progression during the examined period. In these 32 cases, representing 72·7% (32/44) of all patients experiencing relapse, emergence of the BTKC481S mutation preceded the symptoms of clinical relapse with a median of nine months. Subsequent Bcl-2 inhibition therapy applied in 28/32 patients harbouring BTKC481S and progressing on ibrutinib conferred clinical and molecular remission across the patients. Our study demonstrates the clinical value of sensitive BTKC481S monitoring with the largest longitudinally analysed real-world patient cohort reported to date and validates the feasibility of an early prediction of relapse in the majority of ibrutinib-treated relapsed/refractory CLL patients experiencing disease progression.
引用
- Bödör C, Kotmayer L, László T, et al. Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. Br J Haematol. 2021. PMID: 34019713. doi:10.1111/bjh.17502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。